The Anticoagulation Clinic

Chapter

Abstract

Anticoagulant drug therapy presents significant risks of life-threatening bleeding and treatment failure resulting in thromboembolic complications. Safe and effective anticoagulation relies upon an organized system of care delivery, close collaboration between healthcare teams, effective communication with patients, and anticoagulation management performed by healthcare professionals with specialized training. The anticoagulation management service (AMS) was developed to meet these objectives in efforts to optimize warfarin management. The vitamin K antagonist notorious for its complex pharmacology was the only oral anticoagulant option for more than 50 years, and it took most of that time to sort out how to use it well. The introduction of the direct oral anticoagulants (DOACs) has not marginalized the AMS. The core AMS functions remain to determine the appropriateness of anticoagulant therapy, manage anticoagulant dosing, provide systematic and ongoing patient monitoring, provide up-front and ongoing patient education, and coordinate with other providers involved in the care of anticoagulated patients. The availability of DOACs has added another critical AMS function which is to assist providers in selecting the correct anticoagulant for an individual patient. This chapter reviews structural elements to support AMS success in the delivery of optimized anticoagulation care.

Keywords

Warfarin Vitamin K antagonist Anticoagulant Anticoagulation management Anticoagulation program International normalized ratio Prothrombin time Monitoring Management Direct oral anticoagulant 

References

  1. 1.
    Ansell JE, Buttaro ML, Thomas OV, Knowlton CH. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ann Pharmacother. 1997;31:604–15.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. Arch Intern Med. 1977;137:197–202.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Reinders TP, Steinke WE. Pharmacist management of anticoagulant therapy in ambulant patients. Am J Hosp Pharm. 1979;36:645–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Witte K, Gurwich EL, Anzalone R, Campagna MA. Audit of an oral anticoagulant teaching program. Am J Hosp Pharm. 1980;37:89–91.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Zhou S, Sheng XY, Xiang Q, Wang ZN, Zhou Y, Cui YM. Comparing the effectiveness of pharmacist-managed warfarin anticoagulation with other models: a systematic review and meta-analysis. J Clin Pharm Ther. 2016;41:602–11.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S–84S.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Garcia DA, Witt DM, Hylek E, et al. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008;42:979–88.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wirth D, Moore J. Developing a business plan for an anticoagulation management service. In: Ansell J, Oertel L, Wittkowsky A, editors. Managing oral anticoagulation therapy: clinical and operational guidelines. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2009.Google Scholar
  10. 10.
    Vadher BD, Patterson DL, Leaning M. Comparison of oral anticoagulant control by a nurse-practitioner using a computer decision-support system with that by clinicians. Clin Lab Haematol. 1997;19:203–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Fitzmaurice DA, Murray ET, Allan TF, Holder RL, Rose PE, Hobbs FD. A comparison of international normalised ratio (INR) measurement in hospital and general practice settings: evidence for lack of standardisation. J Clin Pathol. 2000;53:803-4.CrossRefPubMedGoogle Scholar
  12. 12.
    Donovan JL, Drake JA, Whittaker P, Tran MT. Pharmacy-managed anticoagulation: assessment of in-hospital efficacy and evaluation of financial impact and community acceptance. J Thromb Thrombolysis. 2006;22:23–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Locke C, Ravnan SL, Patel R, Uchizono JA. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy. 2005;25:685–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Schillig J, Kaatz S, Hudson M, Krol GD, Szandzik EG, Kalus JS. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011;6:322–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127:1515–22.CrossRefPubMedGoogle Scholar
  16. 16.
    Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30:330–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Nutescu EA, Bathija S, Sharp LK, Gerber BS, Schumock GT, Fitzgibbon ML. Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoption. Pharmacotherapy. 2011;31:1161–74.CrossRefPubMedGoogle Scholar
  18. 18.
    Dorfman DM, Goonan EM, Boutilier MK, Jarolim P, Tanasijevica M, Goldhaber SZ. Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation. Vasc Med. 2005;10:23–7.CrossRefGoogle Scholar
  19. 19.
    McCahon D, Murray ET, Jowett S, et al. Patient self management of oral anticoagulation in routine care in the UK. J Clin Pathol. 2007;60:1263–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Simmons BJ, Jenner KM, Delate T, Clark NP, Kurz D, Witt DM. Pilot study of a novel patient self-management program for warfarin therapy using venipuncture-acquired international normalized ratio monitoring. Pharmacotherapy. 2012;32:1078–84.CrossRefPubMedGoogle Scholar
  21. 21.
    Jenner KM, Simmons BJ, Delate T, Clark NP, Kurz D, Witt DM. An education program for patient self-management of Warfarin. Perm J. 2015;19:33–8.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363:1608–20.CrossRefPubMedGoogle Scholar
  23. 23.
    Heneghan CJ, Garcia-Alamino JM, Spencer EA, et al. Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev. 2016;7:CD003839.PubMedGoogle Scholar
  24. 24.
    Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest. 2006;130:1385–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Bishop MA, Streiff MB. Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients. J Thromb Thrombolysis. 2016;42:283–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47:804–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Poller L, Keown M, Ibrahim S, et al. A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. Thromb Haemost. 2009;101:487–94.PubMedGoogle Scholar
  28. 28.
    Nieuwlaat R, Hubers LM, Spyropoulos AC, et al. Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. Thromb Haemost. 2012;108:1228–35.CrossRefPubMedGoogle Scholar
  29. 29.
    National Certification Board for Anticoagulation Providers (NCBAP). https://www.ncbap.org/index.aspx.
  30. 30.
    Anticoagulation Forum Centers of Excellence. http://excellence.acforum.org/.
  31. 31.
    Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011;155:653–9. W201-3.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Witt DM, Delate T, Clark NP, et al. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010;8:744–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Clark NP. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008;123(Suppl 1):S58–61.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006;296:935–42.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Parker CS, Chen Z, Price M, et al. Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med. 2007;22(9):1254.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Witt DM, Delate T, Clark NP, et al. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013;132:e124–30.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167:810–7.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost. 2015;13:495–504.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Doherty JU, Gluckman TJ, Hucker WJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69:871–98.CrossRefGoogle Scholar
  40. 40.
    Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823–33.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e326S–50S.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. Haematologica. 2002;87:1081–6.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Estrada CA, Hryniewicz MM, Higgs VB, Collins C, Byrd JC. Anticoagulant patient information material is written at high readability levels. Stroke. 2000;31:2966–70.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Moore SJ, Blair EA, Steeb DR, Reed BN, Hull JH, Rodgers JE. Impact of video technology on efficiency of pharmacist-provided anticoagulation counseling and patient comprehension. Ann Pharmacother. 2015;49:631–8.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Witt DM. Quality measures and benchmarking for warfarin therapy. J Thromb Thrombolysis. 2011;31:242–8.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126:2309–16.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15:213–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Ibrahim S, Jespersen J, Poller L, European Action on Anticoagulation. The clinical evaluation of international normalized ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost. 2013;11:1540–6.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993;118:511–20.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost. 2008;6:451–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Nieuwlaat R, Barker L, Kim YK, et al. Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. Thromb Res. 2010;125:e128–31.CrossRefPubMedGoogle Scholar
  52. 52.
    Kim YK, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost. 2010;8:101–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Fihn SD, McDonell MB, Vermes D, et al. A computerized intervention to improve timing of outpatient follow-up: a multicenter randomized trial in patients treated with warfarin. National Consortium of Anticoagulation Clinics. J Gen Intern Med. 1994;9:131–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011;4:276–82.CrossRefPubMedGoogle Scholar
  55. 55.
    Rose AJ, Ozonoff A, Berlowitz DR, Ash AS, Reisman JI, Hylek EM. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the veterans Affairs study to improve anticoagulation. Chest. 2011;140:359–65.CrossRefPubMedGoogle Scholar
  56. 56.
    Rose AJ, Miller DR, Ozonoff A, et al. Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest. 2013;143:751–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Kauffman YS, Schroeder AE, Witt DM. Patient specific factors influencing adherence to INR monitoring. Pharmacotherapy. 2015;35:740–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Zallman L, Bearse A, West C, Bor D, McCormick D. Patient preferences and access to text messaging for health care reminders in a safety-net setting. Inform Health Soc Care. 2017;42:32–42.CrossRefPubMedGoogle Scholar
  59. 59.
    Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost. 2009;7:94–101.CrossRefGoogle Scholar
  60. 60.
    King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261–95.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Rose AJ, Berlowitz DR, Miller DR, et al. INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2012;10:590–5.CrossRefPubMedGoogle Scholar
  62. 62.
    Hysong SJ, Sawhney MK, Wilson L, et al. Improving outpatient safety through effective electronic communication: a study protocol. Implement Sci. 2009;4:62.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4:22–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Rose AJ, Delate T, Ozonoff A, Witt DM. Comparison of the abilities of summary measures of international normalized ratio control to predict clinically relevant bleeding. Circ Cardiovasc Qual Outcomes. 2015;8:524–31.CrossRefPubMedGoogle Scholar
  65. 65.
    Barnes GD, Nallamothu BK, Sales AE, Froehlich JB. Reimagining anticoagulation clinics in the era of direct oral anticoagulants. Circ Cardiovasc Qual Outcomes. 2016;9:182–5.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Chowdhry U, Jacques A, Karovitch A, Giguere P, Nguyen ML. Appropriateness of dabigatran and rivaroxaban prescribing for hospital inpatients. Can J Hosp Pharm. 2016;69:194–201.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131:972–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinical Pharmacy Anticoagulation and Anemia Service, Kaiser Permanente ColoradoAuroraUSA
  2. 2.University of Utah College of PharmacySalt Lake CityUSA

Personalised recommendations